De Quervain’s tenosynovitis: a non-randomized two-armed study comparing ultrasound-guided steroid injection with surgical release

Under aseptic conditions, a Philips IU 22 USG machine and 12.3 Hz linear probe were used to visualize cross-sectional anatomy of the first extensor compartment. A 20-gauge needle was used to inject 2 cc of 2% lignocaine and 20 mg methylprednisolone acetate (20 mg/ml) into the first extensor compartment of the wrist around the APL and EPB tendons.

If a separate compartment was noted for EPB, the injection was split equally for both the compartments with similar infiltration techniques under USG guidance (Fig. 1b). Special care was taken to avoid the sensory branches of the radial nerve. Patients undergoing injections were advised a thumb spica splint and light work for 3 weeks followed by resumption of their routine activities.

A single-hand surgeon performed all surgical releases. A transverse incision was made and decompression of the first extensor compartment was completed, ensuring the release of any sub-compartment and checking the excursion of EPB and APL separately. They were immobilized in a thumb spica slab for 3 days and later mobilized in a thumb spica splint for a further 3 weeks. This was followed by the resumption of their activities.

We reviewed all patients after 3 and 6 weeks and 6 months for the functional outcome, recurrence, or any complications. We used the disabilities of arm, shoulder and hand (DASH) score, patient rated wrist evaluation (PRWE) score, and visual analogue score (VAS) [13, 16]. The 30-item self-reported DASH questionnaire looks at the patient’s ability to perform specific upper extremity activities and difficulty and interference with daily life. The score is documented on a 5-point Likert scale. PRWE is a 15-item questionnaire used for specific wrist problems and was developed to assess wrist pain and disability in activities of daily living. It has two subscales of pain and function and each of them has an item (five for pain and 10 for function) rated from 1 to 10. The maximum score for each of these two sections is 50 and the minimum is 0. The VAS is a widely used unidimensional measure of pain intensity. We followed a simple method in using a straight horizontal line of 10 cm orientated from the left (worst – maximum pain at 10 cm mark) to the right (best – no pain at zero mark). The patient marks the point on the line, which they perceive to be their current state of pain at the site of pathology. The lesser the score suggests a better outcome in all the three scores.

We chose 6 months as this was the maximum likely time gap after which recurrence was unlikely to be reported [10, 29]. However, patients who returned back after 6 months were also assessed based on their symptoms and signs and their status documented. Patients who did not improve after the single steroid injection and had a relapse of symptoms was planned to be treated surgically. Relapse rate and intraoperative findings were to be recorded to establish etiology.

The mean DASH, PRWE and VAS scores of patients in both the groups improved marginally following the initial conservative management of 4 weeks, which was found to be insignificant (Table 2).

At 6 weeks, both the group of patients showed significant improvement (Table 2). The DASH/PRWE/VAS scores improved from 82.2/81.5/6.7 to 1.7/3.4/1.0, respectively for patients undergoing surgery (Table 2). Similarly, for a patient undergoing USG guided steroid injection, the scores improved from 81.7/79.3/6.8 to 1.0/1.7/1.0, respectively (Table 2). At the end of 6 months, there was a statistically significant difference in both the groups (p < 0.05) and were comparable to each other.

We did not observe recurrence in either group at the end of 6 months of follow-up. Twelve patients came for follow-up after 6 months out of which seven had received USG guided steroid injections. Those patients had an average follow-up of 14.5 months (12–24 months). Two patients who had received USG guided steroid injections showed recurrence, which was observed at eight and 10 months, respectively after the index injection. Both of them incidentally had a single compartment for EPB tendon on USG evaluation. One of them was a 35-years-old computer software professional who presented 8 months after the injection. She had symptoms for 4 weeks prior to the presentation. Another patient was a 59-year-old homemaker who had a history of soft tissue trauma involving the wrist 8 months after the index injection. She presented to us 2 months later with symptoms of recurrence. Both patients were unwilling for surgery and hence continued on medications and splinting.

Apart from two patients with recurrence, two other patients reported pain only on heavy work and the rest had complete relief of symptoms and returned to their daily activities.

Out of those 30 patients who underwent surgical release, three had scar tenderness, which resolved by the 6th month follow-up. Two patients have decreased sensations over the surgical scar and the rest had complete relief of symptoms.

Corticosteroid injection is a popular option for musculoskeletal disorders ever since their introduction in the 1950s [4]. RCTs and systematic review of RCTs in the last two decades have consistently shown their benefit in de Quervain’s tenosynovitis [1, 4, 12, 13]. Rowland et al. did a systematic review, which included Five RCTs with 142 patients receiving corticosteroid injection with an overall follow-up period of 5.6 months (1.5–12 months) [13]. They showed resolution rates of symptoms higher than the controls (2.59 vs. 5.37, (p = 0.05)). The steroid group demonstrated better pain relief as measured by the visual analogue scale (VAS) and improvement in Dutch AIMS-HFF and DASH scores that were statistically significant [13]. Our study confirms the benefit observed with steroids but we additionally used the advantage of an ultrasound-guided procedure. We conducted this study to test our hypothesis that USG guided steroid injection is equally effective as surgery. We observed that USG guided steroid injections are comparable to surgical release in terms of pain relief, functional outcome, complications.

Blind steroid injection has a high chance of missing the separate compartment for EPB and hence leading to relapse or incomplete relief. Ultrasound has been used as a key tool for the diagnosis of de Quervain’s tenosynovitis and more importantly for subtle anatomical variations like separate compartments for APL and EPB. Additionally, its use to deliver steroids when compared to blind injection has significantly improved outcomes as shown in some of the reports [21‐26] (Table 3). In a series of 50 cadavers, Leversedge et al. showed an accuracy rate of 94% in the diagnosing presence of sub-compartments within the first compartment using USG. Their USG -guided injection accuracy was 100% and EPB compartment injection 96% [24]. Another study, by Kang et al. in a series of 15 fresh cadavers, demonstrated not only a higher accuracy for USG guided injections (93.3% vs. 40%) to target the first extensor compartment but also better results when separate septum was present (85.7% vs. 16.7%) [30]. In a cadaver model involving 43 specimens comparing USG and anatomical landmark (AL) guided injection, Kutsikovich et al. showed that both techniques had an infiltration rate of 100% [32]. In the presence of a septum, the USG group achieved a higher infiltration rate in EPB sub-compartments of 75% accuracy in reaching the sub-compartment when compared to 33% in AL. Although statistically unconfirmed, they stated that USG aided injections in the presence of a septum [32]. In our series, more than 50% of patients had a separate sub-compartment and none of them came back with recurrence of symptoms, suggesting the effectiveness of USG guided injections.

Similar results were observed in clinical studies [18, 20, 22, 24]. In a series of 43 wrists who were evaluated with USG, Kwon et al. showed a sensitivity of 100% and a specificity of 96% with a positive predictive value of 95% in diagnosing an intra-compartmental septum [20]. Kume et al. did an RCT involving 44 wrists comparing blind injections with USG guided injections [18]. At 4 weeks, they reported a significant decrease in the VAS scores in the USG group from 80.3 to 25.6 mm(p = 0.004) when compared to the manual group (from 78.0 to 58.2 mm(p = 0.04)) after injection [19]. Their results suggested that USG guided injections targeted the septation of EPB better than the blind injections [19]. However, there have been reports which have questioned the advantage of the use of USG including those with reports of increased chance of failure particularly with the presence of a sub-compartment [16, 23, 31, 32]. Nevertheless, its benefit and use are still advocated in view of a higher chance of placement of the needle at the pathological site [23, 31, 32]. In a level 1, study of randomized comparison between blind and USG guided injection involving 44 patients, Shin et al. observed sustained improvement in PRWE and pain scores at 4 and 12 weeks post-injection [16]. The authors observed that at 3 months, 10% in USG showed recurrence of symptoms, which was marginally better than 26.3% in the blind group although this was statistically not significant [16]. In our study, we observed a benefit of USG-guided steroid injection after 6 months of follow up which was statistically significant. Sustained benefit of injections was seen in 93.7% of our patients. None of the patients with higher risks for recurrence, came back with relapse of symptoms. The major advantage of a USG guided procedure lies in its ability to diagnose the condition, checking for anatomical variability, while helping in counselling the patient on the prognosis of the condition [22]. Additionally, it helps in the accurate placement of the needle at the right pathological site [22]. The procedure is relatively inexpensive in our country costing $15 in our institution and hardly takes a little more time than blind injections, which incidentally costs $10. In the two patients with recurrence that was observed in our series after 6 months, we observed a common compartment for APL and EPB. In one of the patients who was a computer professional, we were unable to find the exact etiology. In the other, a homemaker, the soft tissue injury may have independently triggered a new episode. Incidentally, no studies have established an association between hand usage at work or trauma with this condition [33].

The literature continues to report complications associated with surgery like wound infections, delayed wound healing, radial nerve injury, scar hypertrophy and tenderness [27, 34]. In this regard, the role of USG guided steroid injections becomes important as recent reports suggest equally impressive results with them as well [19, 21‐26]. Hence we aimed to address the question of whether USG guided injections offers a success rate comparable to surgery apart from its obvious advantage of saving time, cost and logistics for both patients, surgeons and insurance. There are no studies on comparison between the above two extremely effective procedures. Our study fills this information gap with a unique study comparing the two with respect to functional outcomes, recurrence and complications over a period of 6 months follow-up with a further assessment for recurrence for a maximum of 2 years.

Surgical release of the first extensor compartment has been the gold standard for de Quervain’s tenosynovitis [34]. Long-term follow-up studies have shown impressive results with no reports of recurrence [27, 28] (Table 3). In a series involving 94 patients undergoing surgical release with an average follow-up of 15.7 years, Scheller et al. achieved complete relief of symptoms and normal return to daily activities in all their patients [27]. Garcon et al. also reported no recurrence and a satisfaction rate of 97.5% in a series of 89 patients with follow-up of 9.5 years [28]. Our results of surgery confirm similar outcomes with no recurrences and improvements in functional outcome scores that were statistically significant. We noted that patients who underwent surgical release for de Quervain’s tenosynovitis had significant relief even on the first follow-up after surgery, and the same was maintained until the final follow-up. The total percentage change in DASH scores, PRWE scores and VAS scores at 6 months was also significant. This suggests that surgery is an effective treatment for de Quervain’s tenosynovitis.

However, in our study, USG guided steroid injection provided equally rewarding results as surgery did. We observed significant and sustained relief in the patients treated with USG guided steroid injection and the results are comparable with other studies done for the same [16, 19, 21‐29, 29, 30, 30, 31, 31, 32, 32‐39]. Steroid injections when given under USG guidance can yield results, which are as good as surgery and avoid complications related to surgery and blind injections.

Most of the studies noted good relief in the first 4–6 weeks of follow-up after which relapse of symptoms may be observed [10, 11, 13, 14, 16, 23, 31, 37]. However, the pattern of relief and the time of recurrence with the need for a second injection remains variable [9]. Majority of the studies have reported recurrence by 6–12 weeks [9, 14, 18, 20, 30, 37] (Table 3). Earp et al. have reported relief in more than half among a series of 50 consecutive patients who were followed up over a year after a single-blind steroid injection for de Quervain’s tenosynovitis [29]. In their opinion, recurrence wase observed within the first 6 months of follow-up [29]. These recurrences are significantly lower at 6 months whenever USG guided injections were used as nearly 3/4th of patients showed significant relief in other series [22, 23, 29, 31]. Even with USG guided injections, recurrences were observed more frequently in the presence of a separate septum [22, 31]. In one report, Hajdar et al. achieved 73% success after single USG guided injections with all recurrences being observed by 9 months similar to that of our patients [22]. Similarly, Keating-Hart et al. achieved 91% success initially, which was sustained at 76% at the end of the year with five patients each showing recurrence in the initial 6 weeks and later half, respectively [31]. Considering this fact, USG becomes an advantageous tool to counsel our patients on the prognosis of the condition while giving the injections. None of our patients required the need for a surgery even after 1 year of follow-up except two, which justifies the use of USG guided injections ahead of surgery. Literature has noted problems of hypopigmentation, flare reaction, radial nerve symptoms, thrombophlebitis, and weakness of grip strength with steroid injections [1, 10, 16] (Table 3). We did not observe any such adverse reactions in our study.

Incidentally, our patients did not have any significant complications in surgery also, other than minor sensory disturbances at the affected site.

The strength of our study lies in achieving adequate matching of demographics from a similar pool of population while pursuing treatment during the same time period. We have used the DASH, PRWE and VAS scores for the outcome analysis as each of these scores have been shown to correlate with each other well and has also been used for assessment of function following both surgery and steroid injections in past studies [16, 38].

Limitations of our study lie in our inability to provide accuracy rates of diagnostic USG for comparison with therapeutic procedure findings as the injections, imaging evaluations and surgery were all done by different consultants. Although it was not the aim, functional scores at 1-year follow-up would have added value to our study. As expected, most of our patients’ visits were untimely and irregular after 6 months, which is the case in most clinical conditions where patients get optimum relief. Hence, other than features of recurrence, functional scores would not have been useful for comparison. We have not done a detailed evaluation after 6 months, as this was not the aim of the study and have only evaluated for recurrence due to which we were unable to provide long-term follow-up results. However, recurrences are far much lesser after 6 months as reported in literature [29, 37].

Based on our observations, perhaps future studies could involve comparing the role of site and type of needle placement based on USG findings with various combinations of steroids along with hyaluronic acid preparations [25, 26]. The advent of WALANT technique for de Quervain’s and its benefits in recent RCTs opens up its utility for comparison with USG guided techniques as well [39].